TSMC Announces Up to 10% Price Hike for Advanced Chips Starting 2027
Analyst forecasts show Intel and Samsung struggling to close the gap on A16 and N2 technology.
Already have an account? Sign in.
Analyst forecasts show Intel and Samsung struggling to close the gap on A16 and N2 technology.
Roth Capital maintains a Buy rating with a $9 price target despite the post-deal share decline.
BMO Capital gives Trevi Therapeutics an Outperform rating and $36 target, citing strong potential for Haduvio as a first-in-class treatment for chronic cough in idiopathic pulmonary fibrosis.
Genuine Parts lowered its 2026 profit outlook amid weaker consumer demand. CEO Will Stengel denied rumors of a rival acquiring its automotive business.